p53 dysregulation in myelodysplastic syndrome.

被引：0
|
作者：
Totzke, G [1 ]
Sachinidis, A [1 ]
Vetter, H [1 ]
Ko, Y [1 ]
机构：
[1] Univ Bonn, Med Poliklin, D-53111 Bonn, Germany
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3809
引用
收藏
页码：190B / 190B
页数：1
相关论文
共 50 条
  • [21] P53 AND PUMA EXPRESSIONS IN BONE MARROW BIOPSIES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
    Bektas, O.
    Uner, A.
    Buyukasik, Y.
    Uz, B.
    Eliacik, E.
    Isik, A.
    Haznedaroglu, I.
    Goker, H.
    Demiroglu, H.
    Aksu, S.
    Ozcebe, O.
    Sayinalp, N.
    HAEMATOLOGICA, 2012, 97 : 369 - 369
  • [22] Evaluation of P53 protein expression in patients with Myelodysplastic Syndrome (MDS): Prognostic impact
    Cascardi, E.
    Napoli, A.
    Ingravallo, G.
    Specchia, G.
    Maiorano, E.
    Resta, L.
    VIRCHOWS ARCHIV, 2016, 469 : S111 - S112
  • [23] p53 codon 72 polymorphism and cancer risk in Li-Fraumeni syndrome.
    Yip, L
    Hwang, SJ
    Strong, LC
    Lozano, G
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 471 - 471
  • [24] p53 Dysregulation in Breast Cancer: Insights on Mutations in the TP53 Network and p53 Isoform Expression
    Reinhardt, Luiza Steffens
    Groen, Kira
    Xavier, Alexandre
    Avery-Kiejda, Kelly A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (12)
  • [25] IS INACTIVATION OF THE P53 GENE A COMMON EVENT IN LEUKEMIAS AND MYELODYSPLASTIC SYNDROME WITH MONOSOMY 17P
    NAKAI, H
    KANEKO, H
    NAKAO, M
    HORIIKE, S
    MISAWA, S
    LEUKEMIA, 1994, 8 (07) : 1247 - 1248
  • [26] Role of p53 aggregation in dysregulation of autophagy in cancer
    Mir, S. S.
    CANCER MEDICINE, 2018, 7 : 23 - 24
  • [27] Significance of P53 Immunostaining in the Diagnosis of Myelodysplastic Syndromes
    Taheri, Z. Mohammad
    Pournazari, P.
    Auer, I.
    Mansoor, A.
    Luider, J.
    Torbatian, M.
    Shabani-Rad, M-T
    LABORATORY INVESTIGATION, 2012, 92 : 356A - 356A
  • [28] Significance of P53 Immunostaining in the Diagnosis of Myelodysplastic Syndromes
    Taheri, Z. Mohammad
    Pournazari, P.
    Auer, I.
    Mansoor, A.
    Luider, J.
    Torbatian, M.
    Shabani-Rad, M-T
    MODERN PATHOLOGY, 2012, 25 : 356A - 356A
  • [29] Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation
    Guo, Yixuan
    Liu, Zhaoyun
    Duan, Lixiang
    Shen, Hongli
    Ding, Kai
    Fu, Rong
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (04) : 738 - 746
  • [30] Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation
    Yixuan Guo
    Zhaoyun Liu
    Lixiang Duan
    Hongli Shen
    Kai Ding
    Rong Fu
    Investigational New Drugs, 2022, 40 : 738 - 746
12345